{
    "status": "ok",
    "totalResults": 8,
    "articles": [
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Short Interest in IceCure Medical Ltd (NASDAQ:ICCM) Expands By 21.5%",
            "description": "IceCure Medical Ltd (NASDAQ:ICCM \u2013 Get Free Report) was the recipient of a large growth in short interest in November. As of November 15th, there was short interest totalling 439,600 shares, a growth of 21.5% from the October 31st total of 361,700 shares. Bas\u2026",
            "url": "https://www.etfdailynews.com/2023/12/03/short-interest-in-icecure-medical-ltd-nasdaqiccm-expands-by-21-5/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/icecure-medical-ltd-logo.png?v=20211203084913&w=240&h=240&zc=2",
            "publishedAt": "2023-12-03T20:24:42Z",
            "content": "IceCure Medical Ltd (NASDAQ:ICCM \u2013 Get Free Report) was the recipient of a large growth in short interest in November. As of November 15th, there was short interest totalling 439,600 shares, a growth\u2026 [+3053 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "IceCure's ProSense\u00ae Deepens Regulatory Approval in India",
            "description": "(marketscreener.com) \n\nProSense\u00ae is already marketed and sold in India based on previous regulatory requirements and now has been re-classified due to new regulationsBreast cancer cryoablation is already performed in India with ProSense\u00aeCAESAREA, Israel, Nov.\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ICECURE-MEDICAL-LTD-120795404/news/IceCure-s-ProSense-Deepens-Regulatory-Approval-in-India-45461984/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-11-29T13:01:14Z",
            "content": "<ul><li>ProSense\u00ae is already marketed and sold in India based on previous regulatory requirements and now has been re-classified due to new regulations</li><li>Breast cancer cryoablation is already p\u2026 [+5100 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "IceCure Medical (ICCM) to Release Quarterly Earnings on Wednesday",
            "description": "IceCure Medical (NASDAQ:ICCM \u2013 Get Free Report) is set to release its earnings data before the market opens on Wednesday, November 15th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter. IceCure Medical (NASDAQ:ICCM \u2013 Get \u2026",
            "url": "https://www.etfdailynews.com/2023/11/09/icecure-medical-iccm-to-release-quarterly-earnings-on-wednesday/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/icecure-medical-ltd-logo.png?v=20211203084913&w=240&h=240&zc=2",
            "publishedAt": "2023-11-09T15:14:48Z",
            "content": "IceCure Medical (NASDAQ:ICCM \u2013 Get Free Report) is set to release its earnings data before the market opens on Wednesday, November 15th. Analysts expect the company to announce earnings of ($0.09) pe\u2026 [+3435 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "IceCure Medical Files Appeal with U.S. FDA Requesting a Review of its De Novo Classification for ProSense\u00ae in Early-Stage Breast Cancer",
            "description": "(marketscreener.com) \n\nObjective is to reopen file to address comments and find appropriate comparator group that is more representative of the patient population the Company is seeking to treat with its\u00a0ProSense\u00ae systemCompany seeks to complete the review pr\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ICECURE-MEDICAL-LTD-120795404/news/IceCure-Medical-Files-Appeal-with-U-S-FDA-Requesting-a-Review-of-its-De-Novo-Classification-for-Pro-45360199/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-11-15T12:31:04Z",
            "content": "<ul><li>Objective is to reopen file to address comments and find appropriate comparator group that is more representative of the patient population the Company is seeking to treat with its\u00a0ProSense\u00ae \u2026 [+7265 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "IceCure Medical Reports Financial Results as of and for the Nine Months Ended September 30, 2023, and Provides Update on Recent Operational Highlights",
            "description": "(marketscreener.com) \n\nProSense\u00ae system and disposables sales continue upward trend compared to the equivalent prior year periodExpanded regulatory footprint, growing body of evidenced-based data, and distribution agreements demonstrate an increasing acceptan\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ICECURE-MEDICAL-LTD-120795404/news/IceCure-Medical-Reports-Financial-Results-as-of-and-for-the-Nine-Months-Ended-September-30-2023-an-45360493/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-11-15T13:01:15Z",
            "content": "<ul><li>ProSense\u00ae system and disposables sales continue upward trend compared to the equivalent prior year period</li><li>Expanded regulatory footprint, growing body of evidenced-based data, and dist\u2026 [+29909 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "IceCure System Successfully Treated Kidney Cancer Tumor with 92% Disease-Free Survival Rate and 100% Secondary Local Control Rate",
            "description": "(marketscreener.com) \n\nIndependent study concluded:- IceCure system offers significant advantage in ability to re-treat tumors that are initially resistant, achieving a subsequent local control rate of 100%- 92.4% of patients were discharged the day after cyr\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ICECURE-MEDICAL-LTD-120795404/news/IceCure-System-Successfully-Treated-Kidney-Cancer-Tumor-with-92-Disease-Free-Survival-Rate-and-100-45451449/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-11-28T13:01:16Z",
            "content": "<ul><li>Independent study concluded:- IceCure system offers significant advantage in ability to re-treat tumors that are initially resistant, achieving a subsequent local control rate of 100%- 92.4% \u2026 [+7986 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "IceCure Medical\u2019s (ICCM) \u201cBuy\u201d Rating Reaffirmed at HC Wainwright",
            "description": "IceCure Medical (NASDAQ:ICCM \u2013 Get Free Report)\u2018s stock had its \u201cbuy\u201d rating restated by analysts at HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $3.00 price objective on the stock. HC Wainwright\u2019s\u2026",
            "url": "https://www.etfdailynews.com/2023/11/29/icecure-medicals-iccm-buy-rating-reaffirmed-at-hc-wainwright/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/icecure-medical-ltd-logo.png?v=20211203084913&w=240&h=240&zc=2",
            "publishedAt": "2023-11-29T13:16:42Z",
            "content": "IceCure Medical (NASDAQ:ICCM \u2013 Get Free Report)\u2018s stock had its \u201cbuy\u201d rating restated by analysts at HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports. They presentl\u2026 [+2662 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "InvestorsObserver"
            },
            "author": "InvestorsObserver",
            "title": "Healthcare Stocks Making Moves Tuesday: RDHL, ICCM, GYRE, CDIO, AXLA, CABA, BDRX, SEEL",
            "description": "These Healthcare stocks are trading higher:\n-RedHill Biopharma Ltd (RDHL) stock is trading at $1.90, a rise of $0.9, or 91.99%, on high volume.  Redhill Biophrma ADR gets a Senti",
            "url": "https://www.investorsobserver.com/news/stock-update/healthcare-stocks-making-moves-tuesday-rdhl-iccm-gyre-cdio-axla-caba-bdrx-seel",
            "urlToImage": "https://s3.amazonaws.com/images.investorsobserver.com/wp-content/uploads/2020/08/12105709/Dropper-Adding-Fluid-To-Test-Tube.jpg",
            "publishedAt": "2023-11-28T14:27:12Z",
            "content": "These Healthcare stocks are trading higher:\r\n-RedHill Biopharma Ltd (RDHL) stock is trading at $1.90, a rise of $0.9, or 91.99%, on high volume. Redhill Biophrma ADR gets a Sentiment Score of Very Bu\u2026 [+1986 chars]"
        }
    ]
}